Search research articles
Contact Us
Filters
Showing results (161-170 of 210) with videos related to
Page
of 21
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Cell Reports. Medicine
|
August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinoma
Marie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Cancer Immunology Research
|
November 19, 2016
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M Awad, Robert E Jones, Hongye Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
The New England Journal of Medicine
|
April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)
|
February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
JTO Clinical and Research Reports
|
October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
Biagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
Page
of 21
Search research articles
Search
Showing results (161-170 of 210) with videos related to
Sort By:
Page
of 21
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2017
Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring <i>MET</i> Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models
Lars D Engstrom, Ruth Aranda, Matthew Lee, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2019
First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers
Neal Ready, Matthew D Hellmann, Mark M Awad, et al.
Cell Reports. Medicine
|
August 2, 2024
In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF<sup>V600E</sup> lung adenocarcinoma
Marie-Julie Nokin, Elodie Darbo, Elodie Richard, et al.
Cancer Immunology Research
|
November 19, 2016
Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors
Mark M Awad, Robert E Jones, Hongye Liu, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLC
Joao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung Cancer
Rohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 27, 2025
First-line MET tyrosine kinase inhibitors versus immunotherapy ± chemotherapy for patients with MET exon 14 skipping mutant metastatic NSCLC
Federica Pecci, Hui Li, Alessandro Di Federico, et al.
The New England Journal of Medicine
|
April 11, 2022
Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
Future Oncology (London, England)
|
February 23, 2023
Plain language summary of the CheckMate 816 study results: nivolumab plus chemotherapy given before surgery for non-small-cell lung cancer
Patrick M Forde, Jonathan Spicer, Shun Lu, et al.
JTO Clinical and Research Reports
|
October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or Cemiplimab
Biagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.
Page
of 21